ssf-2-leukemia-codesystem
type: CodeSystem
node role: treeRoot
id:
  v: ssf-2-leukemia-codesystem
text:
  status:
    v: generated
  div: Generated Narrative: CodeSystem ssf-2-leukemia-codesystem This case-sensitive code system https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem defines the following codes: Code Display 000 正常 001 AML with RUNX1-RUNX1T1 002 AML with CBFB-MYH11 003 Acute promyelocytic leukemia with PML-RARA 004 AML with KMT2A-MLLT3 005 AML with DEK-NUP214 006 AML with GATA2, MECOM 007 AML(megakaryoblastic) with RBM15-MKL1 008 AML with mutated NPM1 009 AML with biallelic mutation of CEBPA 010 AML with mutated FLT3/ITD 011 AML with mutated FLT3/TKD 012 AML with MLL-PTD (partial tandem duplication) 013 AML with BCR-ABL1 021 B lymphoblastic leukemia/lymphoma with BCR-ABL1 022 B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged 023 B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1) 024 B-lymphoblastic leukemia/lymphoma with IGH/IL3 025 B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1) 041 Mixed phenotype acute leukemia with BCR-ABL1 042 Mixed-phenotype acute leukemia with KMT2A-rearranged 051 Chronic myelogenous leukemia BCR-ABL1 positive 052 JAK2 V617F mutation 053 Myeloid and lymphoid neoplasms with PDGFRA rearrangement 054 Myeloid and lymphoid neoplasms with PDGFRB rearrangement 055 Myeloid and lymphoid neoplasms with FGFR1 rearrangement 090 (1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常 091 同時有兩種(含)以上上述之分子檢驗異常 092 同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常 8XX Molecular study after chemotherapy or immunotherapy or target therapy 988 不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4) 998 有執行分子生物學檢查，但結果無法判斷 999 (1) 病歷未記載或不詳 (2) 未執行分子生物學檢查
url:
  v: https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem
version:
  v: 0.1.1
name:
  v: SSF2leukemiaCS
title:
  v: SSF2 白血病-白血病分子生物學檢查的評估代碼系統
status:
  v: active
experimental:
  v: false
date:
  v: 2024-08-01T15:33:47+08:00
publisher:
  v: Kuo
contact:
  name:
    v: Kuo
  telecom:
    system:
      v: url
    value:
      v: http://example.org/example-publisher
description:
  v: Assessment of molecular studies in leukemia Code System
case sensitive:
  v: true
content:
  v: complete
count:
  v: 33
concept:
  code:
    v: 000
  display:
    v: 正常
concept:
  code:
    v: 001
  display:
    v: AML with RUNX1-RUNX1T1
concept:
  code:
    v: 002
  display:
    v: AML with CBFB-MYH11
concept:
  code:
    v: 003
  display:
    v: Acute promyelocytic leukemia with PML-RARA
concept:
  code:
    v: 004
  display:
    v: AML with KMT2A-MLLT3
concept:
  code:
    v: 005
  display:
    v: AML with DEK-NUP214
concept:
  code:
    v: 006
  display:
    v: AML with GATA2, MECOM
concept:
  code:
    v: 007
  display:
    v: AML(megakaryoblastic) with RBM15-MKL1
concept:
  code:
    v: 008
  display:
    v: AML with mutated NPM1
concept:
  code:
    v: 009
  display:
    v: AML with biallelic mutation of CEBPA
concept:
  code:
    v: 010
  display:
    v: AML with mutated FLT3/ITD
concept:
  code:
    v: 011
  display:
    v: AML with mutated FLT3/TKD
concept:
  code:
    v: 012
  display:
    v: AML with MLL-PTD (partial tandem duplication)
concept:
  code:
    v: 013
  display:
    v: AML with BCR-ABL1
concept:
  code:
    v: 021
  display:
    v: B lymphoblastic leukemia/lymphoma with BCR-ABL1
concept:
  code:
    v: 022
  display:
    v: B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged
concept:
  code:
    v: 023
  display:
    v: B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)
concept:
  code:
    v: 024
  display:
    v: B-lymphoblastic leukemia/lymphoma with IGH/IL3
concept:
  code:
    v: 025
  display:
    v: B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)
concept:
  code:
    v: 041
  display:
    v: Mixed phenotype acute leukemia with BCR-ABL1
concept:
  code:
    v: 042
  display:
    v: Mixed-phenotype acute leukemia with KMT2A-rearranged
concept:
  code:
    v: 051
  display:
    v: Chronic myelogenous leukemia BCR-ABL1 positive
concept:
  code:
    v: 052
  display:
    v: JAK2 V617F mutation
concept:
  code:
    v: 053
  display:
    v: Myeloid and lymphoid neoplasms with PDGFRA rearrangement
concept:
  code:
    v: 054
  display:
    v: Myeloid and lymphoid neoplasms with PDGFRB rearrangement
concept:
  code:
    v: 055
  display:
    v: Myeloid and lymphoid neoplasms with FGFR1 rearrangement
concept:
  code:
    v: 090
  display:
    v: (1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常
concept:
  code:
    v: 091
  display:
    v: 同時有兩種(含)以上上述之分子檢驗異常
concept:
  code:
    v: 092
  display:
    v: 同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常
concept:
  code:
    v: 8XX
  display:
    v: Molecular study after chemotherapy or immunotherapy or target therapy
concept:
  code:
    v: 988
  display:
    v: 不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)
concept:
  code:
    v: 998
  display:
    v: 有執行分子生物學檢查，但結果無法判斷

code:
  v: 999
display:
  v: (1) 病歷未記載或不詳 (2) 未執行分子生物學檢查